Bell, Matthew http://orcid.org/0000-0003-4313-2989
Lange, Shannon
Sejdiu, Besian I.
Ibanez, Jorge http://orcid.org/0000-0003-4317-8573
Shi, Hao
Sun, Xiang
Meng, Xiaoxi
Nguyen, Phuong
Sutton, Morgan
Wagner, Jessica http://orcid.org/0000-0003-2587-3310
KC, Anil
Langfitt, Deanna http://orcid.org/0000-0003-0941-5360
Patil, Sagar L.
Tan, Haiyan
Pandey, Ram Vinay
Li, Yuxin
Yuan, Zuo-Fei
Anido, Alejandro Allo http://orcid.org/0000-0002-5794-9992
Ho, Mitchell http://orcid.org/0000-0002-9152-5405
Sheppard, Heather
Vogel, Peter
Yu, Jiyang http://orcid.org/0000-0003-3629-4330
Peng, Junmin
Chi, Hongbo
Babu, M. Madan http://orcid.org/0000-0003-0556-6196
Krenciute, Giedre http://orcid.org/0000-0003-4335-0644
Gottschalk, Stephen http://orcid.org/0000-0003-3991-7468
Funding for this research was provided by:
American Lebanese Syrian Associated Charities
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31CA250401-01A1)
U.S. Department of Health & Human Services | National Institutes of Health (R01NS121249, R01NS122859)
Article History
Received: 24 October 2022
Accepted: 20 October 2023
First Online: 30 November 2023
Competing interests
: M.B., B.I.S., A.A.A., M.M.B., G.K. and S.G. are coinventors on a patent application for the developed Zip receptor technology. S.L., A.A.A., G.K. and S.G. are coinventors on patent applications in the fields of cell or gene therapy for cancer. M.H. is an inventor on international patent application no. PCT/US2019/045338 assigned to NIH, ‘High affinity monoclonal antibodies targeting glypican-2 and uses thereof’. H.C. is a consultant of Kumquat Biosciences, Inc. S.G. is a consultant of TESSA Therapeutics, a member of the Data and Safety Monitoring Board of Immatics and has received honoraria from Tidal, Catamaran Bio, Sanofi and Novartis within the past 2 years. The other authors declare no competing interests.